Peptide Therapy and HRT: How Peptides Complement Hormone Replacement

Key Takeaways

• Compounds covered: GH secretagogues (sermorelin, ipamorelin, CJC-1295), BPC-157, kisspeptin
• Goal area: Complementing HRT in perimenopausal and postmenopausal women
• Evidence range: Ranges from limited clinical data on GH secretagogues for body composition to preclinical animal studies for BPC-157; kisspeptin research is mechanistically detailed but lacks HRT-combination trial data
• Regulatory range: GH secretagogues are not FDA-approved; BPC-157 is FDA Category 2 (compounding restricted); kisspeptin is not FDA-approved for menopause indications
• Key biomarkers for this goal: IGF-1, estradiol, FSH, LH, progesterone, hs-CRP, comprehensive metabolic panel
• As of April 2026: No peptide discussed in this article is FDA-approved as an adjunct to HRT. Following the February 2026 FDA determination, BPC-157 is not eligible for compounding under Section 503A; no licensed U.S. compounding pathway currently exists. As of April 22, 2026, CJC-1295 and ipamorelin are additionally subject to an FDA PCAC recommendation against 503A inclusion; sermorelin remains on the Category 1 pathway.
• Bottom line: HRT addresses sex hormone deficiency; peptides target parallel axes — GH, tissue repair, and HPG signaling — that estrogen replacement alone does not cover.

Understanding the Biology: What HRT Addresses and What It Does Not

Hormone replacement therapy is designed to replace estrogen and progesterone — the hormones whose withdrawal during menopause drives the hallmark symptoms: vasomotor episodes (hot flushes, night sweats), urogenital atrophy, accelerated bone loss, and mood disruption. A 2026 review by Lephart in Life documented HRT effects on skin and bone alongside selected cardiovascular biomarkers and the historical hesitancy following the Women's Health Initiative. When initiated close to menopause onset, well-individualized HRT addresses much of the hormonal deficit driving these symptoms.

What HRT does not address is somatopause. Sattler, in a 2013 review in Best Practice and Research: Clinical Endocrinology and Metabolism, characterized somatopause as the progressive decline of GH and IGF-1 secretion with aging — a process that begins in the third decade and proceeds independently of ovarian hormone status. Di Somma and colleagues, reviewing somatopause in Minerva Endocrinologica in 2011, documented clinical consequences including increased fat mass and impaired bone density, reduced lean mass, and reduced exercise capacity — all of which overlap substantially with menopause symptomatology but originate in a separate hormonal axis.

Three additional biological gaps persist on standard HRT: musculoskeletal symptoms including joint pain and tendon vulnerability, HPG axis signaling dynamics that estrogen does not fully normalize, and sexual health dimensions beyond the vaginal and urogenital effects that estrogen directly addresses. These gaps are where peptide research is most active.

Peptides Studied Alongside HRT: A Quick Comparison

The following peptides have published evidence relevant to mechanisms that persist or develop despite HRT. They are ordered by evidence strength.

• Compound: GH secretagogues (sermorelin, ipamorelin, CJC-1295)
  Mechanism for this goal: Stimulate pituitary GH release via GHRH receptor or ghrelin receptor, elevating IGF-1 and supporting lean mass and fat metabolism alongside but independent of estrogen
  Evidence: Limited clinical data in mixed populations; no HRT-combination RCT
  FDA status: Not FDA-approved for menopause or body composition. Sermorelin (Geref) was FDA-approved in 1997 for pediatric GH deficiency and was withdrawn from the U.S. market in 2008; no FDA-approved sermorelin product is currently marketed. Current clinical sermorelin access is through 503A compounding from a Category 1 bulk substance. Ipamorelin and CJC-1295 (without DAC) — never FDA-approved; subject to an April 22, 2026 FDA PCAC recommendation against inclusion on the 503A bulk drug substances list; access through compounding pharmacies is narrowing
  SP availability: Sermorelin is available through licensed providers on the Superpower platform following clinical evaluation; availability of other GH secretagogues (CJC-1295 without DAC, ipamorelin) may vary and should be confirmed at consultation. All GH secretagogues through Superpower are dispensed by licensed 503A compounding pharmacies against a patient-specific prescription
  Route: Subcutaneous injection
• Compound: BPC-157
  Mechanism for this goal: Cytoprotective pentadecapeptide with proposed tissue-repair activity in tendons, ligaments, and soft tissue via VEGFR2 activation and nitric oxide signaling
  Evidence: Animal studies; one clinical case series; no RCT in menopausal women
  FDA status: Not FDA-approved. Following the February 2026 FDA determination, BPC-157 is not eligible for 503A compounding; no lawful U.S. compounding pathway currently exists
  SP availability: Not currently available through Superpower
  Route: Subcutaneous injection or oral (bioavailability disputed)
• Compound: Kisspeptin
  Mechanism for this goal: Upstream HPG axis neuropeptide that drives GnRH and LH pulse dynamics; may modulate neuroendocrine dimensions of hot flushes and sexual function
  Evidence: Mechanistic research; limited human pharmacology studies; no menopause-specific RCT
  FDA status: Not FDA-approved for any menopause indication
  SP availability: Not currently available through Superpower for this indication
  Route: IV/subcutaneous in research settings
• Compound: Collagen peptides
  Mechanism for this goal: Oral hydrolyzed collagen fragments may support dermal thickness and joint matrix — areas where estrogen decline accelerates collagen degradation
  Evidence: Phase II/RCT data for skin outcomes; limited joint data
  FDA status: Regulated as dietary supplements; not FDA-approved as drugs
  SP availability: Widely available as dietary supplements
  Route: Oral

BPC-157 is not currently eligible for 503A compounding following the February 2026 FDA determination. Kisspeptin is not available through U.S. compounding pharmacies for menopause indications. GH secretagogues (sermorelin, ipamorelin, CJC-1295 without DAC) remain available through 503A compounding with a valid patient-specific prescription. Inclusion of restricted compounds here is for educational context only.

Peptides Studied Alongside HRT: Individual Profiles

Each compound targets a distinct mechanism. A provider evaluating peptides as HRT adjuncts will assess these separately — they have different evidence bases, different regulatory statuses, and different monitoring requirements.

GH secretagogues for body composition

GH secretagogues are compounds that stimulate the pituitary to release endogenous growth hormone — either through GHRH receptor agonism (sermorelin, CJC-1295) or ghrelin receptor agonism (ipamorelin, MK-677). Their relevance alongside HRT stems from somatopause: the age-related decline of GH and IGF-1 that proceeds on a separate trajectory from ovarian hormone loss.

Mandelli and colleagues, in a 2022 review in Climacteric, reviewed estrogens' role in osteosarcopenia and the potential dual therapeutic effects of estrogens on both bone and muscle. Sinha and colleagues, in a 2020 review in Translational Andrology and Urology on GH secretagogues in hypogonadal males, documented preliminary lean mass and fat effects — a mechanism that has not been tested in women at menopause, and no HRT-combination trial has been completed for GH secretagogues. Rolland and colleagues, reviewing current and investigational medications for sarcopenia in Metabolism in 2023, positioned GH secretagogues as emerging adjuncts for muscle mass preservation in aging populations — a category that includes women on HRT who still experience progressive lean mass loss. [Limited clinical data; no HRT-combination RCT]

A 24-month rhGH-replacement study by Kościuszko and colleagues in adults with documented GH deficiency, published in International Journal of Molecular Sciences in 2026, showed cardiovascular biomarker improvements with rhGH alongside body composition gains — data that are mechanistically analogous rather than directly applicable, but support the monitoring rationale for IGF-1 and metabolic markers when adding GH secretagogues to any regimen. Monitoring IGF-1 during GH secretagogue use is standard practice — supraphysiologic IGF-1 carries theoretical proliferative risk, which requires provider oversight. GH secretagogues are not FDA-approved for menopause or body composition indications.

BPC-157 for musculoskeletal symptoms

BPC-157 (body protection compound 157) is a synthetic pentadecapeptide derived from a gastric protein with proposed cytoprotective, angiogenic, and tissue-repair properties. Its relevance alongside HRT is motivated by the fact that HRT does not fully resolve the musculoskeletal syndrome of menopause.

Wright and colleagues, in a 2024 review in Climacteric, documented joint pain, tendon injury, and muscle symptoms as a recognized musculoskeletal syndrome of menopause that HRT alone does not consistently address. Strand and colleagues, reviewing pain during menopause in Maturitas in 2025, reported that musculoskeletal pain persists despite HRT in a substantial proportion of women. Seiwerth and colleagues, in a 2021 review in Frontiers in Pharmacology, reviewed BPC-157's wound-healing and tissue-repair properties across multiple preclinical models. Gwyer and colleagues, in a 2019 review in Cell and Tissue Research, reviewed preclinical evidence for BPC-157's mechanism in musculoskeletal soft tissue healing, including VEGFR2 activation and upregulation of angiogenic signaling in animal models. [Animal study; limited human case series]

Lee and colleagues published a case series of BPC-157 for knee pain in Alternative Therapies in Health and Medicine in 2021, reporting improvements in knee pain scores — the most direct human evidence for musculoskeletal benefit, though not an RCT. As of April 2026, following the February 2026 FDA determination, BPC-157 is not eligible for compounding under Section 503A; no lawful U.S. compounding pathway currently exists. It is not FDA-approved for any indication. BPC-157 is not available through Superpower or any licensed prescriber for this indication.

Kisspeptin for HPG axis and hot flush support

Kisspeptin is a neuropeptide produced by KNDy neurons in the hypothalamus that serves as the principal upstream activator of GnRH release — and thus the LH and FSH pulses that regulate gonadal function. Its relevance in the menopause context extends beyond reproductive physiology: kisspeptin neurons are also implicated in the generation of hot flushes.

Miragem and colleagues, in a 2017 review in Human Reproduction Update, reviewed hot flush mechanisms including the nitric oxide and heat shock protein axis — documenting the neuroendocrine underpinning of vasomotor symptoms that HRT partially modulates. Kauffman, in a 2022 review in Frontiers in Neuroscience, reviewed how kisspeptin neurons mediate estrogen positive feedback onto GnRH neurons to generate the preovulatory LH surge — kisspeptin signaling that exogenous estrogen in HRT does not fully recapitulate — a key mechanistic distinction. Xu and colleagues, in a 2026 comprehensive review in Comprehensive Physiology, detailed kisspeptin cross-talk across HPG axes in perimenopausal women, characterizing the signaling gaps that persist on HRT. [Mechanistic research; no RCT in menopausal populations]

Kisspeptin is not FDA-approved for any menopause indication and is not available through Superpower for this use. Research is ongoing in academic settings, but no Phase 3 or Phase 2 RCT addressing kisspeptin as an HRT adjunct has been published.

Collagen peptides for skin and joint matrix

Estrogen plays a recognized role in maintaining skin collagen content — dermal thickness declines significantly in the years immediately following menopause onset, and HRT partially mitigates this loss. Widgerow and colleagues, in a 2026 review in the Journal of Cosmetic Dermatology, reviewed menopause-related dermal white adipose depletion and regenerative therapeutic approaches — dermal structural changes that extend beyond the collagen and hydration dimensions estrogen replacement most directly addresses. Lee and colleagues, in a 2025 RCT published in the Journal of Microbiology and Biotechnology, demonstrated that collagen peptides improved skin elasticity and hydration in healthy adults (not specifically menopausal women) — recent clinical evidence for oral collagen as a skin adjunct, extrapolated to the menopausal population. [Phase II/RCT for skin outcomes; limited joint data]

Collagen peptides are regulated as dietary supplements, not drugs. They do not require a prescription and are not subject to FDA drug approval requirements. They should not be conflated with injectable GH-axis peptides in terms of mechanism, evidence base, or risk profile.

Regulatory Status at a Glance

As of April 2026, the compounds discussed in this article carry different regulatory statuses.

• GH secretagogues: Sermorelin — Not FDA-approved for menopause, body composition, or HRT adjunct indications. Sermorelin (Geref) was FDA-approved in 1997 for pediatric GHD and was withdrawn from the U.S. market in 2008; no FDA-approved sermorelin product is currently marketed. Current clinical sermorelin access is through 503A compounding from a Category 1 bulk substance with a valid patient-specific prescription. Ipamorelin and CJC-1295 (without DAC) — Not FDA-approved for any indication. On April 22, 2026, the FDA Pharmacy Compounding Advisory Committee (PCAC) recommended against including these two peptides on the 503A bulk drug substances list; access through compounding pharmacies is subject to FDA's final determination and may be restricted. CJC-1295 with DAC — has a less settled 503A status and may not be uniformly available; not addressed by the April 22, 2026 PCAC action.
• BPC-157: Not FDA-approved for any indication. Following the February 2026 FDA determination, BPC-157 is not eligible for compounding under Section 503A; no lawful U.S. compounding pathway currently exists.
• Kisspeptin: Not FDA-approved for any indication. Kisspeptin material marketed online is typically labeled "For Research Use Only" and is not legally intended for human administration; no lawful U.S. route exists for self-administration.
• Collagen peptides: Regulated as dietary supplements under DSHEA. Not FDA-approved drugs. Not subject to drug approval requirements.

Research-use-only (RUO) labeled material is not legally intended for human use and cannot be legally compounded into a human-use prescription; self-administration is outside authorized U.S. distribution channels. Inclusion of such compounds in this article is for educational context only.

Considerations When Comparing Peptides for HRT Integration

Selecting an HRT adjunct is a clinical decision made by a licensed provider who can evaluate the complete picture: current HRT regimen, symptom burden, baseline labs, and personal health history. The compounds in this article address different mechanisms and require separate evaluation.

Direct comparison between these compounds is not straightforward — they have been studied in different populations, at different doses, and using different endpoints. Inferring relative effectiveness from separate trials is methodologically unreliable.

Your specific persistent symptom on HRT: Body composition changes and lean mass loss favor GH secretagogue evaluation. Residual joint pain and musculoskeletal symptoms are mechanistically relevant to BPC-157's preclinical tissue-repair evidence, though — following the February 2026 FDA determination — BPC-157 is not currently available through any lawful U.S. compounding pathway, so clinical discussion is limited to whether future regulatory changes would reopen access. Persistent hot flushes or libido changes may bring kisspeptin into the clinical conversation; PT-141 (bremelanotide) is FDA-approved as Vyleesi for premenopausal hypoactive sexual desire disorder, and its use in postmenopausal populations is off-label with limited evidence.

Existing health conditions and baseline labs: A history of hormone-sensitive malignancy is a consideration with any compound that intersects GH or sex hormone signaling. IGF-1 levels before starting any GH secretagogue are essential. Estradiol and gonadotropin levels characterize HRT effectiveness. Liver and kidney function guide safety assessment for any injectable compound.

Evidence level: GH secretagogues have the most human data among the non-approved compounds on this page — modest but real. BPC-157 has compelling preclinical data and one case series. Kisspeptin research is mechanistically rich but has not progressed to menopause-specific clinical trials. A provider will factor evidence level into any recommendation.

Regulatory status: BPC-157 compounding is currently restricted. GH secretagogue availability through licensed providers varies. These are not consumer decisions — they require a clinical evaluation.

This is not an exhaustive list of clinical considerations. A licensed provider will evaluate your full health history, current medications, and baseline lab results before recommending any compound.

Safety Considerations

Safety profiles across these compounds vary substantially. No blanket statement about their safety applies.

GH secretagogues carry the most defined risk profile among the non-approved compounds here: elevated IGF-1, water retention, and joint discomfort are documented effects of supraphysiologic GH stimulation. Monitoring IGF-1 levels within the reference range is standard clinical practice during GH secretagogue use. BPC-157 has no documented adverse effects in preclinical models, but the absence of systematic human safety data means its long-term risk profile is unknown. Kisspeptin pharmacology in humans is characterized in research settings but clinical safety data for extended use as an HRT adjunct does not exist. Liu and colleagues, in a 2026 cohort study in Maturitas, examined exogenous hormone use and dementia in 273,069 UK women, finding HRT not linked to dementia risk — part of an evolving evidence base on HRT's long-term safety that frames how any adjunct discussion is conducted.

Broad contraindications relevant to this use-case context include:

• Personal or family history of hormone-sensitive malignancy — GH-axis compounds carry theoretical proliferative concerns not specifically studied in HRT populations
• Pregnancy or breastfeeding — no reproductive safety data exists for any investigational peptide in this list
• Active insulin resistance or type 2 diabetes — GH secretagogues can affect glucose metabolism; baseline fasting insulin and HbA1c are essential
• Known hypersensitivity to any component of a compounded formulation
• Gray-market injectable sources — products sold outside licensed pharmacy channels are not legally intended for human use and carry contamination, identity, and dosing risks that cannot be mitigated by the end user

For compound-specific side effect profiles, see the individual compound pages linked above.

What to Test Before Starting Peptides Alongside HRT

Regardless of which compound you and your provider discuss, baseline biomarker testing establishes a measurable starting point. Without it, there is no objective way to assess whether a compound is producing the expected physiological changes — or whether those changes are beneficial.

• IGF-1: The primary downstream marker of GH axis activity. Mandatory before any GH secretagogue — establishes whether the GH-IGF-1 axis is functioning within range and provides the reference point for monitoring during therapy. Supraphysiologic IGF-1 is a clinical concern requiring provider management.
• Estradiol: Characterizes current estrogen status and how effectively existing HRT is replacing it. Essential for understanding the hormonal context before adding any adjunct compound.
• FSH and LH: Gonadotropin levels reflect the HPG axis baseline and the degree of ovarian suppression on HRT. Relevant for kisspeptin context and for characterizing where in the menopause transition a patient stands.
• Progesterone: Relevant if micronized progesterone is part of the HRT regimen. Memi and colleagues, in a 2024 review in Reviews in Endocrine and Metabolic Disorders, reviewed micronized progesterone's role in reproductive regulation — establishing the baseline is important before adding any compound that may interact with progesterone signaling.
• hs-CRP: Systemic inflammation marker. Relevant for any tissue-repair compound context and for characterizing inflammatory burden as baseline. Menopause itself is associated with elevated low-grade inflammation.
• Liver enzymes (ALT, AST) and eGFR: Safety baseline for any injectable compound. Liver and kidney function affect peptide pharmacokinetics. The liver health biomarker panel provides comprehensive baseline data for anyone considering injectable peptide therapy.
• Fasting insulin and HbA1c: GH secretagogues can affect glucose metabolism. A metabolic baseline characterizes insulin sensitivity before any compound is introduced. The metabolic health biomarker guide covers these markers in detail.

Bone mineral density (DEXA scan) is worth discussing with a provider for any woman adding GH secretagogues or BPC-157 to an HRT regimen, given the lean-mass considerations and the unresolved question of whether GH-axis modulation affects bone outcomes in this population. Subarajan and colleagues, in a 2024 review in Endocrinology and Metabolism Clinics of North America, surveyed biological pathways driving postmenopausal bone loss and current treatment guidelines — reinforcing that biomarker assessment should extend beyond estrogen to include metabolic and GH-axis markers. Liu and colleagues, in a 2025 preclinical (ovariectomized-mouse) study in Life Sciences, investigated FSH's role in osteocyte signaling and bone mass recovery — establishing that bone loss in menopause involves multiple pathways beyond estrogen.

How to Access These Peptides Safely

Every injectable peptide used for therapeutic purposes in the United States requires a prescription from a licensed healthcare provider. Products sold online without a prescription — typically under 'For Research Use Only' labels — are not legally intended for human administration and do not represent a lawful access pathway. The access pathway for any compound here involves a clinical evaluation by a licensed healthcare provider who can review your complete health history, current HRT regimen, baseline labs, and individual risk factors.

GH secretagogues such as sermorelin and ipamorelin remain available through licensed U.S. 503A compounding pharmacies with a valid patient-specific prescription, as Category 1 bulk substances; availability is subject to ongoing FDA classification decisions and individual pharmacy capabilities. Following the February 2026 FDA determination, BPC-157 is not eligible for compounding under Section 503A; no lawful U.S. compounding pathway currently exists. Kisspeptin is not available through licensed prescribers for menopause indications.

For research-only compounds, gray-market products exist but are not on any lawful compounding pathway: 503A pharmacies cannot lawfully compound prescriptions from research-use-only bulk material, and self-administered RUO products are not prepared under USP compounding standards or regulated pharmacy oversight. Purity, potency, and identity cannot be verified by an end user. Superpower does not facilitate access to research-only or FDA Category 2 compounds.

A provider evaluation for peptides alongside HRT typically involves: review of current HRT regimen and symptom burden, comprehensive lab work including the markers listed above, discussion of evidence levels and realistic expectations for each compound, and a monitoring plan for any compound initiated.

Understanding Your Baseline

With multiple compounds available — each targeting different mechanisms and carrying different evidence levels — baseline biomarker data transforms the clinical conversation. The question shifts from "which peptide might help with menopause?" to "what does my hormonal and metabolic profile show, and which biological gaps does my current HRT regimen leave unaddressed?" That is the question a baseline panel answers — and it is the question worth having with a provider before any adjunct is considered.

That principle — test first, then decide — is central to Superpower's approach to preventive health. Whether the conversation with your provider leads to optimized HRT dosing, a GH secretagogue for lean mass, or a watchful-waiting approach, the starting point is the same: knowing where your biomarkers stand.

Important Safety Information

GH secretagogues (sermorelin, ipamorelin, CJC-1295) are not approved by the FDA for any body composition, menopause, or HRT adjunct indication. These compounds are available through compounding pharmacies as not-FDA-approved medications. Their safety and efficacy as adjuncts to hormone replacement therapy have not been established through adequate and well-controlled clinical trials. IGF-1 monitoring is required during use; supraphysiologic IGF-1 carries theoretical risks that have not been fully characterized in this population. Superpower connects members with licensed healthcare providers; prescribing decisions are made by providers, not by Superpower.

BPC-157 is not approved by the FDA for any medical use. Following the February 2026 FDA determination, BPC-157 is not eligible for compounding under Section 503A; no lawful U.S. compounding pathway currently exists. Research on BPC-157 has been limited primarily to laboratory and animal studies. No completed human RCT has evaluated BPC-157 as an HRT adjunct. BPC-157 is not prescribed, compounded, or dispensed through Superpower.

Kisspeptin is not approved by the FDA for any menopause indication. It is not available through US compounding pharmacies for this use. Research on kisspeptin's role in menopausal neuroendocrinology is ongoing but has not produced clinical trial evidence for use as an HRT adjunct. Kisspeptin is not prescribed or dispensed through Superpower.

Collagen peptides are dietary supplements regulated under DSHEA. Statements about dietary supplements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease.

All injectable peptide therapies require a prescription from a licensed healthcare provider. This content is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider, including one experienced in hormone replacement, before starting any peptide compound. Individual health history, current medications, and baseline lab values affect both eligibility and response.

As of April 2026, no completed human RCT has studied any peptide compound specifically as an adjunct to HRT in menopausal women. Evidence cited in this article reflects the best currently available research but should not be construed as clinical evidence of efficacy for this combined use.

Disclaimer: This article discusses investigational peptide compounds and their potential relevance alongside hormone replacement therapy. Some compounds are available through compounding pharmacies; others are not approved for human use and are discussed for educational purposes only. Superpower Health offers some but not all compounds discussed. This educational content is editorially independent.